Valuation: ImmuCell Corporation

Market Cap 99.33M 86.17M 80.84M 73.66M 138M 9.48B 141M 949M 371M 4.75B 373M 365M 15.84B P/E 2024
-19.5x
P/E 2025 -51.3x
Enterprise Value 109M 94.31M 88.49M 80.62M 151M 10.38B 154M 1.04B 406M 5.2B 408M 399M 17.34B EV / Sales 2024
2.16x
EV / Sales 2025 2.35x
Free-Float
67.43%
Yield 2024 *
-
Yield 2025 -
1 day-0.73%
1 week+1.40%
Current month-2.77%
1 month+0.09%
3 months+30.07%
6 months+64.65%
Current year+77.24%
1 week 10.47
Extreme 10.47
11.14
1 month 10.47
Extreme 10.47
12.1
Current year 5.75
Extreme 5.75
12.1
1 year 4.52
Extreme 4.52
12.1
3 years 3.34
Extreme 3.34
12.1
5 years 3.34
Extreme 3.34
12.1
10 years 0
Extreme 0
13.2
Manager TitleAgeSince
Chief Executive Officer 54 2025-10-31
Director of Finance/CFO 47 2025-04-06
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Director/Board Member 64 2026-04-14
Chairman 69 2013-11-30
Director/Board Member 61 2014-03-30
Date Insider Type Main position Quantity % Market Cap.
1/27/26 Free

Chief Financial Officer

120,000 1.3266%
1/27/26 Free

Director

100,000 1.1055%
1/27/26 Free

Chief Executive Officer

109,500 1.2105%
Change 5-day change 1-year change 3-year change Capi.($)
-0.73%+1.40%+63.91%+118.00% 99.33M
-0.92%+3.35%+89.07%+128.86% 1,088B
+0.47%+1.74%+51.68%+50.75% 629B
+0.83%+1.88%+26.27%+64.82% 440B
-0.88%-0.66%+47.04%+36.64% 359B
-0.37%-0.58%+28.59%+36.31% 291B
+0.05%-2.73%+5.61%+6.15% 245B
+0.40%+2.45%+46.62%+59.17% 225B
-0.42%+1.34%-6.94%-51.94% 204B
+1.67%+4.84%+15.10%+72.68% 168B
Average +0.01%+1.03%+36.69%+52.14% 364.93B
Weighted average by Cap. -0.13%+1.93%+49.09%+65.97%

Financials

2024 2025
Net sales 26.49M 22.98M 21.56M 19.65M 36.9M 2.53B 37.54M 253M 98.96M 1.27B 99.43M 97.29M 4.23B 27.64M 23.98M 22.5M 20.5M 38.5M 2.64B 39.17M 264M 103M 1.32B 104M 102M 4.41B
Net income -2.16M -1.87M -1.76M -1.6M -3M -206M -3.06M -20.6M -8.06M -103M -8.09M -7.92M -344M -1.04M -902K -846K -771K -1.45M -99.25M -1.47M -9.94M -3.88M -49.72M -3.9M -3.82M -166M
Net Debt 11.34M 9.84M 9.23M 8.41M 15.8M 1.08B 16.07M 108M 42.36M 542M 42.56M 41.65M 1.81B 9.39M 8.14M 7.64M 6.96M 13.07M 896M 13.3M 89.69M 35.07M 449M 35.23M 34.47M 1.5B
Logo ImmuCell Corporation
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
Employees
73
Date Price Change Volume
26-08-13 US$10.90 -0.73% 43,195
26-08-12 US$10.98 +0.27% 26,828
26-08-11 US$10.95 -0.18% 14,489
26-08-10 US$10.97 -0.27% 12,148
26-08-07 US$11.00 -0.18% 9,705
  1. Stock Market
  2. Stocks
  3. ICCC Stock